GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Krishna Institute of Medical Sciences KIMS.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

721.65

-0.19%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About Krishna Institute of Medical Sciences

Its shares trade on NSE under the ticker KIMS.NS. It has been listed since 28 June 2021. In the fiscal year to 31 March 2026, it reported revenue of ₹39.05bn and net income of ₹2.41bn. At that date it held total assets of ₹77.59bn and shareholders' equity of ₹22.47bn.

Krishna Institute of Medical Sciences Ltd. engages in the provision of healthcare services. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2021-06-28. The Company’s departments include accident, Alzheimer center, andrology and infertility center, pediatric obesity, pediatric oncology, pediatric oncology and hematology center, pediatric orthopedics and rheumatology, pediatric renal center, pediatric surgical center, female urology center, fertility center, gastrointestinal oncology, general surgery, heart wellness center and hepatobiliary surgery center. Its technologies include 4-Arm HD da Vinci Robotic Surgical System, O-Arm Scanner, Novalis Tx Linear Accelerator, 3 Tesla MRI, EBUS, Spy Glass, Mako Robotic for Knee Replacement, and Impella. The Company’s institutes include the institute of Cardiac Sciences, Institute of Dental Science, Institute of Gastroenterology & Hepatology, Institute of Heart & Lung Transplantation, and Institute of Neuro Sciences.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
28 Jun 2021
Employees
10,000
Website
kimshospitals.com ↗

Leadership

Pay as last reported

  • Dr. Bhaskara BollineniExecutive Chairman of the Board, Managing Director, since 2002₹45.0m
  • Dr. Abhinay BollineniChief Executive Officer, Executive Director, since 2019₹26.0m
  • Mr. Sachin SalviChief Financial Officer
  • Dr. Nagajayanthi DasCompany Secretary and Compliance Officer
  • Ms. Anitha DandamudiWhole-time Director, since 2008₹6.8m
  • Mr. Adwik BollineniNon-Executive Non-Independent Director
  • Dr. Saumen ChakrabortyNon-Executive Independent Director₹3.0m
  • Mr. Venkata JasthiNon-Executive Independent Director₹1.5m
  • Mr. Ratna KazaNon-Executive Independent Director₹1.5m
  • Mr. Suresh PatelNon-Executive Independent Director₹350,000
  • Mrs. Prameela YalamanchiliNon-Executive Independent Director₹1.5m

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
77
Environment
86
Social
99
Governance
46
Direct emissions (scope 1)
1,768.05 t
Energy emissions (scope 2)
7,714.31 t
Women in the workforce
51.9%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 10,000 full-time employees.
  • The company has a diverse range of specialized departments including pediatric oncology and hematology.
  • The company utilizes advanced technologies such as the 4-Arm HD da Vinci Robotic Surgical System.

Weaknesses

  • The company's website is not specified beyond the URL provided.
  • The company's IPO date is 2021-06-28, which may indicate limited market history.
  • The company's source description is marked as untrusted, potentially affecting credibility.

Opportunities

  • The company's specialized departments could attract patients seeking niche medical services.
  • Advanced technologies like the 3 Tesla MRI may enhance service quality and patient outcomes.
  • The company's institutes, such as the Institute of Heart & Lung Transplantation, could expand service offerings.

Threats

  • The untrusted source description may lead to misinformation about the company's operations.
  • The company's IPO in 2021-06-28 may face challenges in a competitive healthcare market.
  • The company's reliance on specific technologies could pose risks if they become obsolete.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.